Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 6/2015

Open Access 01-12-2015 | Research Article

Trends in antithrombotic drug use and adherence to non-vitamin K oral anticoagulants in the Netherlands

Authors: Susan Hanemaaijer, Fong Sodihardjo, Annemieke Horikx, Michel Wensing, Peter A. G. M. De Smet, Marcel L. Bouvy, Martina Teichert

Published in: International Journal of Clinical Pharmacy | Issue 6/2015

Login to get access

Abstract

Background Non-vitamin K oral anticoagulants (NOACs) became available in the Netherlands in 2008, providing another antithrombotic treatment besides vitamin K antagonists (VKAs) and antiplatelet agents (APAs). Objective To describe the patterns of antithrombotic drug use between 2008 and 2013 by examination of dispensing data form community pharmacies in the Netherlands; to determine the concomitant use of NOACs with VKAs and APAs and switching between the drug classes; and to compare adherence to NOACs with adherence to APAs. Setting An observational retrospective study was conducted using routinely collected dispensing data from Dutch community pharmacies. Methods For each calendar year, the numbers of NOAC, VKA, and APA users were calculated. Adherence was determined for NOACs and APAs by the percentage of days covered by medication (PDC). Information on the prescribed daily dose of VKAs was unavailable. Main outcome measures Comparison of age, sex, and co-medications of users of the three drug classes; concomitant use of different antithrombotic drug classes and switching between these in each year; and mean PDC and percentages of all users with a PDC above 80 %. Results NOAC use increased during the study period to 29,687 users in 2013. In that year there were 484,024 VKA users and 1313,032 APA users. Compared with users of VKAs, NOAC users were slightly younger and more frequently used antiarrhythmic drugs and beta blockers as co-medications. Substantial numbers of patients were dispensed potentially harmful combinations in 2013: 820 subjects were dispensed NOACs together with VKAs, and 684 subjects were dispensed NOACs, VKAs, and APAs concomitantly. Mean adherence to NOACs was 84.2 % compared with 87.3 % to APA. One in four NOAC users had a PDC lower than 80 % compared with one in five APA users. Conclusion Our findings show increasing use of NOACs by outpatients. The number of patients taking potentially harmful combinations of antithrombotic drugs was substantial. Adherence to NOACs in daily practice may be suboptimal to prevent thrombotic events.
Literature
1.
go back to reference Shameem R, Ansell J. Disadvantages of VKA and requirements for novel anticoagulants. Best Pract Res Clin Haematol. 2013;26:103–14.CrossRefPubMed Shameem R, Ansell J. Disadvantages of VKA and requirements for novel anticoagulants. Best Pract Res Clin Haematol. 2013;26:103–14.CrossRefPubMed
2.
go back to reference Teichert M, Eijgelsheim M, Rivadeneira F, Uitterlinden A, van Schaik R, Hofman A, et al. A genome-wide association study of acenocoumarol maintenance dosage. Hum Mol Genet. 2009;18(19):3758–68.CrossRefPubMed Teichert M, Eijgelsheim M, Rivadeneira F, Uitterlinden A, van Schaik R, Hofman A, et al. A genome-wide association study of acenocoumarol maintenance dosage. Hum Mol Genet. 2009;18(19):3758–68.CrossRefPubMed
3.
go back to reference Teichert M, van Schaik R, Hofman A, Uitterlinden A, de Smet P, Stricker B, et al. Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period. Clin Pharmacol Ther. 2009;85(4):379–86.CrossRefPubMed Teichert M, van Schaik R, Hofman A, Uitterlinden A, de Smet P, Stricker B, et al. Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period. Clin Pharmacol Ther. 2009;85(4):379–86.CrossRefPubMed
4.
go back to reference Bauer K. Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal. Stroke. 2013;44:S38–40.CrossRefPubMed Bauer K. Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal. Stroke. 2013;44:S38–40.CrossRefPubMed
5.
go back to reference Baker W, Cios D, Sander S, Coleman C. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm. 2009;15(3):244–52.PubMed Baker W, Cios D, Sander S, Coleman C. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm. 2009;15(3):244–52.PubMed
6.
go back to reference Blann A, Lip G. Laboratory monitoring of the non-vitamin K oral anticoagulants. J Am Coll Cardiol. 2014;64(11):1140–2.CrossRefPubMed Blann A, Lip G. Laboratory monitoring of the non-vitamin K oral anticoagulants. J Am Coll Cardiol. 2014;64(11):1140–2.CrossRefPubMed
7.
go back to reference Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. Europace. 2015;17(4):514–23.CrossRefPubMed Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. Europace. 2015;17(4):514–23.CrossRefPubMed
8.
9.
go back to reference Camm A, Kirchhof P, Lip G, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation. Eur Heart J. 2010;31:2369–429.CrossRefPubMed Camm A, Kirchhof P, Lip G, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation. Eur Heart J. 2010;31:2369–429.CrossRefPubMed
10.
go back to reference De Caterina R, Husted S, Wallentin L, et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes. J Am Coll Cardiol. 2012;59:1413–25.CrossRefPubMed De Caterina R, Husted S, Wallentin L, et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes. J Am Coll Cardiol. 2012;59:1413–25.CrossRefPubMed
11.
13.
14.
go back to reference Connolly S, Ezekowitz M, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2010;361(12):1139–51.CrossRef Connolly S, Ezekowitz M, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2010;361(12):1139–51.CrossRef
15.
go back to reference Patel M, Mahaffey K, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–9.CrossRefPubMed Patel M, Mahaffey K, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–9.CrossRefPubMed
16.
go back to reference Granger C, Alexander J, McMurray J, Lopes R, Hylek E, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.CrossRefPubMed Granger C, Alexander J, McMurray J, Lopes R, Hylek E, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.CrossRefPubMed
17.
go back to reference Schulman S, Kearon C, Kakkar A, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342–52.CrossRefPubMed Schulman S, Kearon C, Kakkar A, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342–52.CrossRefPubMed
18.
go back to reference Landman G, Gans R. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2011;364(36):2499–510. Landman G, Gans R. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2011;364(36):2499–510.
19.
go back to reference Gómez-Outes A, Terleira-Fernández A, Calvo-Rojas G, Suárez-Gea M, Vargas-Castrillón E. Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of subgroups. Thrombosis. 2013;. doi:10.1155/2013/640723.PubMedCentralPubMed Gómez-Outes A, Terleira-Fernández A, Calvo-Rojas G, Suárez-Gea M, Vargas-Castrillón E. Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of subgroups. Thrombosis. 2013;. doi:10.​1155/​2013/​640723.PubMedCentralPubMed
20.
go back to reference Majeed A, Hwang H, Connolly S, Eikelboom J, Ezekowitz M, Wallentin L, et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation. 2013;128(21):2325–32.CrossRefPubMed Majeed A, Hwang H, Connolly S, Eikelboom J, Ezekowitz M, Wallentin L, et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation. 2013;128(21):2325–32.CrossRefPubMed
22.
go back to reference Sullivan P, Arant T, Ellis S, Ulrich H. The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US. Pharmacoeconomics. 2006;24(10):1021–33.CrossRefPubMed Sullivan P, Arant T, Ellis S, Ulrich H. The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US. Pharmacoeconomics. 2006;24(10):1021–33.CrossRefPubMed
23.
go back to reference Amin A, Deitelzweig S, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, et al. Estimation of the impact of warfarin’s time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials. J Thromb Thrombolysis. 2014;38(2):150–9.CrossRefPubMed Amin A, Deitelzweig S, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, et al. Estimation of the impact of warfarin’s time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials. J Thromb Thrombolysis. 2014;38(2):150–9.CrossRefPubMed
24.
go back to reference Cramer J, Roy A, Burrell A, Fairchild C, Fuldeore M, Ollendorf A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;1098(3015):44–7.CrossRef Cramer J, Roy A, Burrell A, Fairchild C, Fuldeore M, Ollendorf A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;1098(3015):44–7.CrossRef
27.
go back to reference Ogilvie I, Newton N, Welner S, Cowell W, Lip G. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123(7):638–45.CrossRefPubMed Ogilvie I, Newton N, Welner S, Cowell W, Lip G. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123(7):638–45.CrossRefPubMed
28.
go back to reference Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Throm Thrombolysis. 2011;31:326–43.CrossRef Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Throm Thrombolysis. 2011;31:326–43.CrossRef
29.
go back to reference Blaschke T, Osterberg L, Vrijens B, Urquhart J. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol. 2012;52:275–301.CrossRefPubMed Blaschke T, Osterberg L, Vrijens B, Urquhart J. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol. 2012;52:275–301.CrossRefPubMed
30.
go back to reference Beyer-Westendorf J, Förster K, Ebertz F, Gelbricht V, Schreier T, Göbelt M, et al. Drug persistence with rivaroxaban therapy in atrial fibrillation patients results from the Dresden non-interventional oral anticoagulation registry. Europace. 2015;17(4):530–8.PubMedCentralCrossRefPubMed Beyer-Westendorf J, Förster K, Ebertz F, Gelbricht V, Schreier T, Göbelt M, et al. Drug persistence with rivaroxaban therapy in atrial fibrillation patients results from the Dresden non-interventional oral anticoagulation registry. Europace. 2015;17(4):530–8.PubMedCentralCrossRefPubMed
31.
go back to reference Stuurman-Bieze A, Hiddink E, van Boven J, Vegter S. Proactive pharmaceutical care interventions decrease patients’ nonadherence to osteoporosis medication. Osteoporos Int. 2014;25(6):1807–12.PubMed Stuurman-Bieze A, Hiddink E, van Boven J, Vegter S. Proactive pharmaceutical care interventions decrease patients’ nonadherence to osteoporosis medication. Osteoporos Int. 2014;25(6):1807–12.PubMed
32.
go back to reference Suryanarayan D, Schulman S. When the rubber meets the road: adherence and persistence with non-vitamin K antagonist oral anticoagulants and old oral anticoagulants in the real world—a problem or a myth ? Semin Thromb Hemost. 2014;40(8):852–9.CrossRefPubMed Suryanarayan D, Schulman S. When the rubber meets the road: adherence and persistence with non-vitamin K antagonist oral anticoagulants and old oral anticoagulants in the real world—a problem or a myth ? Semin Thromb Hemost. 2014;40(8):852–9.CrossRefPubMed
33.
go back to reference Ewen S, Retting-Ewen V, Mahfoud F, Bohm M, Laufs U. Drug adherence in patients taking oral anticoagulation therapy. Clin Res Cardiol. 1007;2013(10):392. Ewen S, Retting-Ewen V, Mahfoud F, Bohm M, Laufs U. Drug adherence in patients taking oral anticoagulation therapy. Clin Res Cardiol. 1007;2013(10):392.
34.
go back to reference Laliberté F, Cloutier M, Nelson W, Coleman C, Pilon D, Olson W, et al. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin. 2014;30(7):1317–25.CrossRefPubMed Laliberté F, Cloutier M, Nelson W, Coleman C, Pilon D, Olson W, et al. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin. 2014;30(7):1317–25.CrossRefPubMed
35.
go back to reference Schalekamp T, van Geest-Daalderop J, Kramer M, van Holten-Verzantvoort A, de Boer A. Coumarin anticoagulants and co-trimoxazole: avoid the combination rather than manage the interaction. Eur J Clin Pharmacol. 2007;63(4):335–43.PubMedCentralCrossRefPubMed Schalekamp T, van Geest-Daalderop J, Kramer M, van Holten-Verzantvoort A, de Boer A. Coumarin anticoagulants and co-trimoxazole: avoid the combination rather than manage the interaction. Eur J Clin Pharmacol. 2007;63(4):335–43.PubMedCentralCrossRefPubMed
36.
go back to reference Hess P, Mirro M, Diener H, Eikelboom J, Al-Khatib S, Hylek E, et al. Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: proceedings, Washington, DC, December 3–4, 2012. Am Heart J. 2014;168(3):239–47.PubMedCentralCrossRefPubMed Hess P, Mirro M, Diener H, Eikelboom J, Al-Khatib S, Hylek E, et al. Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: proceedings, Washington, DC, December 3–4, 2012. Am Heart J. 2014;168(3):239–47.PubMedCentralCrossRefPubMed
37.
go back to reference Di Minno A, Spadarella G, Tufano A, Prisco D, Di Minno G. Ensuring medication adherence with direct oral anticoagulant drugs: lessons from adherence with vitamin K antagonists (VKAs). Thromb Res. 2014;133(5):699–704.CrossRefPubMed Di Minno A, Spadarella G, Tufano A, Prisco D, Di Minno G. Ensuring medication adherence with direct oral anticoagulant drugs: lessons from adherence with vitamin K antagonists (VKAs). Thromb Res. 2014;133(5):699–704.CrossRefPubMed
38.
go back to reference Vrijens B, Urquhart J. From monitoring to vigilance about patient adherence to new oral anticoagulants. Europace. 2013;16(1):149.CrossRefPubMed Vrijens B, Urquhart J. From monitoring to vigilance about patient adherence to new oral anticoagulants. Europace. 2013;16(1):149.CrossRefPubMed
39.
go back to reference Buurma H, Bouvy ML, De Smet PAGM, Floor-Schreudering A, Leufkens HGM, Egberts ACG. Prevalence and determinants of pharmacy shopping behaviour. J Clin Pharm Ther. 2008;33(1):17–23.CrossRefPubMed Buurma H, Bouvy ML, De Smet PAGM, Floor-Schreudering A, Leufkens HGM, Egberts ACG. Prevalence and determinants of pharmacy shopping behaviour. J Clin Pharm Ther. 2008;33(1):17–23.CrossRefPubMed
Metadata
Title
Trends in antithrombotic drug use and adherence to non-vitamin K oral anticoagulants in the Netherlands
Authors
Susan Hanemaaijer
Fong Sodihardjo
Annemieke Horikx
Michel Wensing
Peter A. G. M. De Smet
Marcel L. Bouvy
Martina Teichert
Publication date
01-12-2015
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 6/2015
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-015-0174-4

Other articles of this Issue 6/2015

International Journal of Clinical Pharmacy 6/2015 Go to the issue